Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Excellent Interview with Matt Coffey - June 2021

<< Previous

Bullboard Posts

Next >>

Comment by Hcallahan44on Nov 16, 2022 2:38pm

172 Views

Post# 35104342

RE:RE:RE:Excellent Interview with Matt Coffey - June 2021

And yet we are heading back to 1.20 a share.....I just dont get it....I think our pay day here is 6-9 months away at minimum like MC is saying.....you would think we would move up and hover hear 10 until further news...but noooooo

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale